Table 4 Selected CAR-T cell trials in relapsed or refractory mantle cell lymphoma
| ZUMA-2 | ZUMA-2 | Transcend | |
|---|---|---|---|
| (KTE-X19) | Update | (Liso-Cel) | |
| Patient | n = 68 | n = 34 | |
| Prior SCT | 43% | 40% | |
| Prior BTKi | 100% | 87.5% | |
| TP53 mutation | 17% | 22% | |
| ORR | 93% | 92% | 84% |
| CR | 67% | 67% | 59% |
| Median DOR | NR | NR | NR |
| PFS | 61% | 59.2% | NR |
| OS | 83% | 67% | NR |
| CRS, any | 91% | NA | 50% |
| ≥ 3 | 15% | 15% | 0% |
| Neurotoxicity, any | 63% | NA | 28% |
| ≥ 3 | 31% | 31% | 9% |
| Neutropenia ≥ 3 | 85% | 85% | 34% |
| Anemia ≥ 3 | 50% | 53% | 31% |
| Thrombocytopenia ≥ 3 | 51% | 53% | 34% |
| TLS ≥ 3 | NA | NA | 3% |
| Grade 5 AE | 3% | 0 | 0 |
| Reference | [9] | [42] | [43] |
| NEJM, 2020 | ASH, 2020 | ASH 2020, #118 |